Cardiac Sympathetic Dysfunction in Genotyped Patients with Arrhythmogenic Right Ventricular Cardiomyopathy and Risk of Recurrent Ventricular Tachyarrhythmias

Matthias Paul[1,2], Thomas Wichter[1], Peter Kies[3], Joachim Gerss[4], Christian Wollmann[1], Kambiz Rahbar[3], Lars Eckardt[1], Günter Breithardt[1], Otmar Schober[3], Eric Schulze-Bahr[1,2], and Michael Schäfers[3,5]

[1]Department of Cardiology and Angiology, University Hospital Münster, Münster, Germany; [2]Institute for Genetics of Heart Diseases, University Hospital Münster, Münster, Germany; [3]Department of Nuclear Medicine, University Hospital Münster, Münster, Germany; [4]Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany; and [5]European Institute for Molecular Imaging (EIMI), University of Münster, Münster, Germany

Patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) typically present with ventricular tachyarrhythmias preferentially triggered by an elevated sympathetic tone. Previous studies demonstrated an impairment of the presynaptic catecholamine reuptake as assessed by ^{123}I-labeled norepinephrine analog on metaiodobenzylguanidine (^{123}I-MIBG) SPECT. Mutations in the gene encoding for plakophilin-2 (PKP-2) are the most common cause of autosomal dominant ARVC (ARVC-9). In this study, we investigated the potential role of adrenergic dysfunction on the arrhythmia profile in patients with ARVC and correlated these findings with the causative genotype. **Methods:** ^{123}I-MIBG SPECT was performed for 42 patients with definite ARVC (10 women, 32 men; mean age ± SD, 43 ± 14 y). Images were acquired at 4 h after injection and analyzed for regional ^{123}I-MIBG uptake in a standardized 33-segment polar map. Results were compared with those obtained from 10 control subjects (5 women, 5 men; mean age ± SD, 43 ± 12 y). **Results:** An abnormal tracer uptake was detected in 25 patients with ARVC (59%). The extents of right ventricular dilation and regional wall motion abnormalities as well as electrocardiographic markers of de- or repolarization were not significantly different between patients with normal and abnormal ^{123}I-MIBG SPECT findings. However, during long-term follow-up of 11.9 ± 4.1 y, patients with abnormal ^{123}I-MIBG SPECT findings experienced life-threatening ventricular tachyarrhythmias significantly more often (22/25 patients [88%]) and independent of the extent of right ventricular dysfunction than those with a normal sympathetic innervation (6/17 patients [35%]; $P < 0.0005$). Mutations in PKP-2 were identified in 17 patients (40%) but were not correlated with the degree of adrenergic dysfunction. **Conclusion:** In patients with ARVC, an impairment of adrenergic innervation independent of the underlying genotype is associated with a higher incidence for future recurrences of ventricular tachyarrhythmias. This finding may suggest a potential role of ^{123}I-MIBG SPECT for individualized risk stratification in ARVC patients and asymptomatic PKP-2 mutation carriers alike.

Identification of new and refinement of existing methods of risk stratification to prevent sudden cardiac arrest is essential. Recent data from a large multicenter trial in heart failure patients highlighted the independent prognostic value of ^{123}I-labeled norepinephrine analog on metaiodobenzylguanidine (^{123}I-MIBG; Covidien) SPECT in assessing the risk of future ventricular tachyarrhythmias (1).

Our group was the first, to our knowledge, to report on regional abnormalities of the presynaptic myocardial sympathetic function using ^{123}I-MIBG SPECT in primarily non–heart-failure patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) (2). This disease is one of the major causes of sudden death in the young. Characteristic localized or diffuse replacement of predominantly right ventricular (RV) myocardium by fibrous fatty tissue gives rise to global and regional RV (and occasionally left ventricular [LV]) dysfunction and causes a predisposition to life-threatening ventricular tachyarrhythmias (3). Pedigree analyses suggested a Mendelian pattern of inheritance, and the majority of mutations identified so far afflict desmosomal proteins as the key architectural components of heart muscle cell integrity, most of them located in the gene encoding for plakophilin-2 (PKP-2) (4). To date, the role of ^{123}I-MIBG SPECT and its potential implication for the arrhythmia profile among other methods of risk stratification (5) in ARVC patients still remain to be elucidated. Therefore, we prospectively evaluated the sympathetic function by ^{123}I-MIBG SPECT, correlated the results with the long-term course of the disease in genotyped patients with ARVC (ARVC-9), and additionally evaluated the role of the genotype in this context.

MATERIALS AND METHODS

Study Patients, Methods, and Control Group

Between March 1992 and July 2003, 42 patients with definite ARVC underwent ^{123}I-MIBG SPECT (10 women, 32 men; mean age ± SD at SPECT scan, 43 ± 14 y). Diagnosis of ARVC was based on detailed noninvasive investigations (12-lead electrocardiogram and transthoracic echocardiography in all patients [100%]; MRI before ^{123}I-MIBG SPECT in 17 patients [40%; Table 1]) and invasive investigations (right and left ventriculography and programmed ventricular stimulation as reported earlier (2) in all patients [100%; Table 1]), in accordance with established and recently modified diagnostic criteria (6). No patient showed clinical signs or symptoms of ischemia; all had normal exercise stress tests as well as normal coronary angiograms.

RV angiography in a biplane view (i.e., 30° right anterior oblique projection; 60° left anterior oblique projection) was used for evaluation of RV size and wall motion (Table 1). RV angiograms were visually evaluated in consensus by 2 experienced cardiologists unaware of the ^{123}I-MIBG SPECT findings as to the extent of global RV dilatation and regional RV dysfunction (absent, moderate, or severe).

The initial arrhythmia manifestation leading to the diagnosis of ARVC encompassed nonsustained ventricular tachycardia (VT; i.e., lasting ≥10 consecutive QRS complexes with spontaneous termination within 30 s), sustained VT (i.e., lasting >30 s or requiring termination due to hemodynamic deterioration), and ventricular fibrillation (VF). The clinical characteristics are summarized in Table 1.

Complete long-term follow-up data were available in all patients. Follow-up started with the date of ^{123}I-MIBG SPECT and ended at the last follow-up visit, heart transplantation, or death (allocated by cause: cardiac vs. noncardiac; death validations were based on the hospital records of the patients' last attended hospital; Table 2). During follow-up, the first occurrence of any sustained VT or VF served as the primary clinical endpoint. Follow-up data were obtained during scheduled visits in our outpatient clinic, during regular telephone calls with patients or referring physicians at regular intervals, and when an adverse event occurred (e.g., VT occurrence). In those patients with an implanted cardioverter defibrillator (ICD), interrogations of the device were scheduled every 3 mo. An ICD therapy (antitachycardic pacing or shock) was classified as appropriate if the stored electrograms or RR intervals retrieved from the ICD confirmed that the tachyarrhythmia before the first treatment by the device was sustained and of ventricular origin.

Molecular genetic analyses from venous blood samples of the ARVC patients and from 380 unrelated controls were performed to detect mutations in the *PKP-2* gene according to the protocol published earlier (4). All coding regions and intron boundaries of the *PKP-2* gene were directly sequenced and compared with reference sequences.

Control Group

Ten patients (5 men, 5 women; mean age ± SD, 43 ± 12 y; P = not significant vs. study group) with medullary carcinoma of

TABLE 1
Clinical Characteristics of Study Patients

Characteristic	ARVC All	MIBG$_{abnormal}$	MIBG$_{normal}$	Controls	P
Patient age at ^{123}I-MIBG scan (y)	43 ± 14	46 ± 14	38 ± 14	43 ± 12	0.211
Patient age at initial diagnosis (y)	40 ± 13	43 ± 14	36 ± 13	—	0.106
Time interval between initial VT ^{123}I-MIBG scan (y)	5.0 ± 7.1	5.8 ± 8.2	3.9 ± 5.1	—	0.419
Patient age at last follow-up (y)	55 ± 15	57 ± 15	51 ± 15	—	0.244
Sex					0.482
Male	32	20	12	5	
Female	10	5	5	5	
Family history (*n*)	8 (19)	4 (16)	4 (24)	—	0.542
MRI available before ^{123}I-MIBG scan (*n*)	17 (40)	9 (36)	8 (47)	—	0.851
Structural abnormalities (RV angiogram)					
RV size					
No RV dilation (*n*)	3 (7)	1 (4)	2 (12)	—	
Moderate RV-dilation (*n*)	27 (64)	16 (64)	11 (65)	—	0.574
Severe RV-dilation (*n*)	12 (29)	8 (32)	4 (23)	—	
RV wall motion					
No abnormalities (*n*)	0	0	0	—	
Moderate abnormalities (*n*)	18 (43)	9 (36)	9 (53)	—	0.276
Severe abnormalities (*n*)	24 (57)	16 (64)	8 (47)	—	
LV involvement (LV angiogram) (*n*)	10 (25)	8 (32)	2 (12)	—	0.131
Electrocardiogram characteristics					
Inverted T-waves (*n*)	2.5 ± 1.8	2.5 ± 1.8	2.6 ± 1.9	—	0.773
Maximal QRS duration (ms)	106 ± 18	108 ± 21	103 ± 14	—	0.369
ε-potential (*n*)	6 (14)	5 (20)	1 (6)	—	0.199
Genetics					
Presence of a *PKP-2* mutation (*n*)	17 (40)	11 (44)	6 (35)	—	0.573

Unless otherwise indicated, data are mean ± SD, and data in parentheses are percentages.

TABLE 2
Arrhythmia Profile of Study Patients

Parameter	ARVC			P
	All	MIBG$_{abnormal}$	MIBG$_{normal}$	
Arrhythmias before initial diagnosis				
Syncope (n)	1 (2)	1 (4)	0	
Nonsustained VT (n)	9 (21)	3 (12)	6 (35)	
Cycle length of nonsustained VT (ms)	308 ± 54	360 ± 14	282 ± 46	0.155
Sustained VT (n)	25 (59)	15 (60)	10 (59)	
Cycle length of sustained VT (ms)	294 ± 56	294 ± 49	295 ± 69	
VF (n)	7 (17)	6 (24)	1 (6)	
Programmed ventricular stimulation				
Inducible sustained VT (n)	30 (71)	21 (84)	9 (53)	0.029
Cycle length of induced VT (ms)	309 ± 107	330 ± 117	254 ± 43	0.089
Implantable cardioverter defibrillator				
Patients with ICD (n)	23 (52)	17 (68)	6 (35)	0.037
Age at first implantation (y)	44 ± 17	48 ± 17	34 ± 18	0.098
Follow-up (after ^{123}I-MIBG SPECT)				
Duration of follow-up (y)	11.9 ± 4.1	11.1 ± 4.4	13.1 ± 3.5	0.111
Patients alive (n)	38 (91)	21 (84)	17 (100)	0.083
Cardiac death (n)	2 (5)	2 (8)	0	
Heart transplantation during follow-up (n)	2 (8)	2 (8)	0	
Patients with VT/VF during follow-up (n)	28 (67)	22 (88)	6 (35)	<0.0005
Time to first VT/VF occurrence (y)	1.9 ± 2.7	1.5 ± 2.5	3.4 ± 3.1	0.122
Classification of arrhythmias				
Nonsustained VT (n)	7 (25)	5 (23)	2 (33)	
Sustained VT (n)	20 (71)	16 (73)	4 (67)	
VF (n)	1 (4)	1 (4)	0	
Cycle length of nonsustained VT during follow-up (ms)	300 ± 72	321 ± 33	272 ± 110	0.426
Cycle length of sustained VT during follow-up (ms)	298 ± 66	295 ± 72	310 ± 35	0.732
Time to first occurrence (y)	1.9 ± 2.7	1.5 ± 2.5	3.4 ± 3.1	0.122

Unless otherwise indicated, data are mean ± SD, and data in parentheses are percentages.

the thyroid gland served as an age-matched control group (*2*). These patients underwent ^{123}I-MIBG SPECT to exclude pheochromocytoma. Results of cardiovascular examination, resting 12-lead electrocardiogram, and exercise tests were normal in all patients. No subject of this group was on drug treatment or had a history, sign, or symptom of cardiac disease or of diseases possibly affecting the cardiac autonomic nervous system.

This study was conducted with the approval of the Ethics Committee of the Chamber of Physicians Westfalen-Lippe and the Medical Faculty of the Westphalian Wilhelms-University Münster, Germany, after informed consent was obtained from the patients.

Data Acquisition and Data Analysis

Cardiac presynaptic sympathetic innervation was assessed by ^{123}I-MIBG SPECT in both controls and ARVC patients. No patient had diabetes mellitus or renal or liver disease, which might influence ^{123}I-MIBG uptake or metabolism.

Data acquisition and processing were performed according to a protocol published earlier (*2,7,8*). In brief, after blockage of the thyroid gland with 300 mg of perchlorate, a dose of 350 MBq of commercially available ^{123}I-MIBG was administered intravenously, and SPECT images were acquired at 4 h after injection. For quantitative analyses, the regional ^{123}I-MIBG uptake in the LV myocardium was measured using a 33-segment polar map analysis as the percentage uptake relative to the segment with maximal uptake (100%). A reduction of tracer uptake in at least 3 adjacent

segments by more than 2 SDs of the mean value of the same segment in the control group was defined as an abnormal reduction of ^{123}I-MIBG uptake. By calculating the total area of abnormal segments of the polar map, the extent of the affected LV myocardium was assessed. Myocardial ^{201}Tl stress-redistribution SPECT, as a parameter for perfusion and viability, was additionally performed in a subgroup of 8 patients to exclude myocardial abnormalities on a small vessel level in the presence of normal coronary angiograms. All patients demonstrated normal ^{201}Tl SPECT perfusion imaging, despite regional defects in ^{123}I-MIBG uptake, thus excluding impaired perfusion as a cause of abnormal ^{123}I-MIBG results. To minimize radiation exposure for the residual study population, we decided not to perform ^{201}Tl SPECT in the entire cohort.

Statistics

Statistical analyses were performed using descriptive and inductive statistical methods. Differences of binary target variables between patients and control subjects were assessed using the χ^2 test. *P* values of less than 0.05 were regarded, in general, to be significant. To identify differences in regional ^{123}I-MIBG uptake, the χ^2 test with Bonferroni adjustment for multiple testing was used. In this case, *P* values of less than 0.002 were considered significant and a *P* of less than 0.05 as borderline significant. Metric data are expressed as mean ± SD. In addition, *z* scores ([segmental value controls − segmental value patient]/SD controls)

were calculated where applicable, to evaluate the depth of the innervation defect (Fig. 1). Differences of metric target variables between groups were assessed by parametric ANOVA or Student t test as appropriate. To account for variable lengths of follow-up, the probability of remaining arrhythmia/event-free survival was analyzed by the Kaplan–Meier method, and differences in event-free survival between groups were evaluated by the log rank test. Additionally multivariate Cox regression analysis was performed. P values of less than 0.05 were considered statistically significant (SPSS, version 16.0 [SPSS Inc.] for Windows [Microsoft]).

RESULTS

^{123}I-MIBG SPECT in ARVC Patients

In the present series of 42 patients with ARVC, 358 (26%) of 1,386 polar map segments showed a significant reduction of LV ^{123}I-MIBG uptake. On the aforementioned criteria, SPECT images were normal in 17 patients (MIBG$_{normal}$; 41%) and classified as abnormal in 25 patients (MIBG$_{abnormal}$; 59%), with a predominantly reduced tracer uptake either in the septal (32%), inferior (31%), or anterior (29%) segments (Fig. 1; Supplemental Table 1 [supplemental materials are available online only at http://jnm.snmjournals.org]).

Clinical Characteristics and Follow-up in ARVC Patients in Relation to ^{123}I-MIBG SPECT

The mean time interval between the first ventricular tachyarrhythmia index event and study entry (i.e., date of ^{123}I-MIBG SPECT) was 5.0 ± 7.1 y. In 14 of 42 patients (33%), sustained ($n = 9$ patients) and nonsustained ($n = 5$ patients) VT occurred between initial diagnosis and ^{123}I-MIBG SPECT, which in arrhythmia type and frequency was not correlated with an abnormal ^{123}I-MIBG uptake in the images acquired later ($P = 0.666$). In the 1 patient with prior syncope, 3 of 9 patients with nonsustained VT, and 21 of 25 patients with sustained VT as initial clinical arrhythmia, sustained VTs were inducible during programmed ventricular stimulation ($P < 0.007$). An ICD was implanted in 23 of the 42 ARVC patients (55%): 7 patients (30%) received an ICD after a survived episode of sudden cardiac arrest; 16 patients (70%) with prior sustained ($n = 14$) or nonsustained VT ($n = 2$) in the presence of an advanced disease manifestation also received an ICD. Baseline clinical characteristics and the length of the follow-up period were not significantly different between the groups (Table 1). However, compared with patients with a normal ^{123}I-MIBG SPECT finding, in MIBG$_{abnormal}$ patients, sustained VTs were more frequently induced during programmed ventricular stimulation (84% vs. 53%; $P = 0.029$; Table 2), and ICDs were more frequently implanted (68% vs. 35%; $P = 0.037$; Table 2).

During long-term follow-up of 11.9 ± 4.1 y, 28 patients (67%) experienced ventricular tachyarrhythmias, which in most cases were classified as sustained VT (71%; Table 2). In patients with ARVC, the mean time to the first VT or VF occurrence was 1.9 ± 2.7 y and did not differ between MIBG$_{abnormal}$ and MIBG$_{normal}$ patients (Table 2). However, MIBG$_{abnormal}$ patients experienced ventricular tachyarrhythmias more often than did MIBG$_{normal}$ patients (88% vs. 35%; $P < 0.0005$; Table 2), resulting in a significantly worse event-free survival in the Kaplan–Meier analyses ($P < 0.001$; Fig. 2). Multivariate Cox regression analysis was performed including the covariates RV size, LV involvement, the presence of an ICD, and an abnormal ^{123}I-MIBG SPECT finding. RV size, ICD, and abnormal ^{123}I-MIBG SPECT finding yet remained independent predictors of a future VT (abnormal ^{123}I-MIBG SPECT: hazard ratio, 4.67; 95% confidence interval, 1.58–13.74; $P = 0.005$; Table 3).

Four patients (9%) died during a mean follow-up of 11.9 ± 4.1 y, 2 of them (both MIBG$_{abnormal}$; Table 2) from progressive biventricular heart failure 14.4 and 14.0 y after the initial diagnosis of ARVC. The other 2 patients died in the wake of carcinoma of the gallbladder and pneumonia. In all cases, the families refused autopsies. Another 2 patients (both MIBG$_{abnormal}$) underwent heart transplantation due to intractable heart failure 5.3 ± 1.7 y after ^{123}I-MIBG SPECT.

Molecular genetic analyses identified mutations in *PKP-2* in 17 ARVC patients (40%). The number of mutation


FIGURE 1. (A) Mean segmental ^{123}I-MIBG uptake (%) in ARVC patients and controls. Differences between patients with normal (MIBG$_{normal}$) and reduced (MIBG$_{abnormal}$) ^{123}I-MIBG uptake in relation to control group (B) are expressed in z scores. Ant = anterior wall segment; Inf = inferior wall segment; Lat = lateral wall segment; Sept = septal wall segment.

FIGURE 2. Event-free survival (i.e., sustained VT) during years of follow-up of study population with normal (MIBG$_{normal}$) vs. abnormal (MIBG$_{abnormal}$) ^{123}I-MIBG uptake. At right are typical ^{123}I-MIBG images.

carriers among patients with abnormal ^{123}I-MIBG SPECT findings was 11 of 25 (44%) and comparable with the 6 mutation carriers among 17 patients (35%) with normal ^{123}I-MIBG SPECT findings ($P = 0.573$; Table 1). During long-term follow-up, Kaplan–Meier analysis of the event-free survival was statistically not significant between MIBG$_{abnormal}$ patients with or without a *PKP-2* gene mutation.

DISCUSSION

There is growing evidence that adrenergic dysfunction assessable by ^{123}I-MIBG SPECT indicates a worse prognosis in patients with heart failure (*1*). In the present study, we could confirm and also expand this finding to the non–heart-failure group of patients with ARVC. The results highlight that ARVC patients with an abnormal ^{123}I-MIBG uptake have a significantly higher propensity for life-threatening ventricular tachyarrhythmias than those with a normal ^{123}I-MIBG SPECT result during long-term follow-up. This finding was independent of the initial extent of the underlying RV dysfunction, and a *PKP-2* genotype did not add to the prognostic value.

Given that ^{123}I-MIBG uptake was assessed at 4 h after injection, no conclusions on the dynamics of ^{123}I-MIBG uptake and release can be drawn. However, the described reduction of tracer activity in the inferior parts of the left ventricle might result from either a reduced reuptake (uptake-1) of ^{123}I-MIBG or catecholamines, an increased release of ^{123}I-MIBG or catecholamines into the synaptic cleft, or a combination of both. All mechanisms would eventually lead to an enhanced catecholamine concentration in the synaptic cleft, with subsequent downregulation of postsynaptic β-adrenoceptor density, as we have previously shown by quantitative PET (*9*).

There was a significantly reduced ^{123}I-MIBG uptake in anterior, septal, and inferior myocardial segments in patients with ARVC ($P < 0.001$; Fig. 1). The uptake of ^{123}I-MIBG is known to be reduced in the inferior wall in the cases of increased parasympathetic tone. This reduction is probably caused by the more pronounced parasympathetic innervation of the inferior LV wall and the RV when compared with the remaining myocardium (*10*), leading to a mismatch between parasympathetic and sympathetic innervation in the inferior wall and resulting in reduced inferior ^{123}I-MIBG uptake. Myocardial hypoperfusion as a potentially confounding source leading to sympathetic dysinnervation appears unlikely in the presence of normal coronary angiograms in all patients and normal ^{201}Tl stress-redistribution SPECT findings in a subset of patients. The definite mechanism linking ^{123}I-MIBG SPECT results with VT or VF recurrences remains yet to be elucidated.

TABLE 3
Predictors of VT During Follow-up Identified by Multivariate Cox Regression

Model	ARVC		
	Hazard ratio (VT)	95% confidence interval	P
Initial			
Structural abnormalities (on angiogram)			
RV size			
Moderate vs. no RV dilation	0.120	0.02–0.74	0.022
Severe vs. no RV dilation	0.147	0.02–1.01	0.051
LV involvement	1.793	0.71–4.56	0.220
Presence of an...			
ICD	3.532	1.23–10.15	0.019
Abnormal ^{123}I-MIBG SPECT finding	4.037	1.35–12.12	0.013
Final			
RV size			
Moderate vs. no RV dilation	0.135	0.02–0.79	0.027
Severe vs. no RV dilation	0.197	0.03–1.24	0.084
Presence of an...			
ICD	3.012	1.08–8.41	0.035
Abnormal ^{123}I-MIBG SPECT finding	4.667	1.58–13.74	0.005

Initial model includes covariates RV size, LV involvement, ICD, and normal/abnormal ^{123}I-MIBG finding, and final model is after (backward) elimination of nonsignificant covariates.

ICD = automatic cardioverter defibrillator; VT = ventricular tachycardia.

Interestingly, the patterns of ^{123}I-MIBG uptake deficiencies (location, size, etc.) were not directly correlated with the resulting type of arrhythmias (nonsustained, sustained VT, etc.) or the frequency of arrhythmias, suggesting a nonlinear relation between a disturbed sympathetic nervous system and the occurrence of ventricular tachyarrhythmias. However, no proof of a causal relationship can be deduced from the present study.

Nevertheless, the observed predisposition to future ventricular tachyarrhythmias in patients with a reduced ^{123}I-MIBG uptake could eventually lead to the recognition of ^{123}I-MIBG SPECT as an indicator of an increased individual risk of future arrhythmic events. This is in line with previous studies in patients with Brugada syndrome (7) or other structural heart diseases (11) and also in a large European multicenter study (12) in which a reduced tracer uptake as a reflection of an autonomic dysfunction was associated with an increased risk of death. These studies, including ours, clearly suggest an emerging role of ^{123}I-MIBG SPECT for individualized risk stratification; the implantation of an ICD could be discussed in those ARVC patients with a sympathetic dysfunction and no prior indication for this device.

The following are limitations of our study. Because the imaging part of the study was already initiated in the 1990s after the first description of ^{123}I-MIBG defects in ARVC worldwide by our group (2), state-of-the-art ^{123}I-MIBG imaging refers to the time of initiating the study and not the current status of ^{123}I-MIBG imaging (i.e., acquisition and 33-segment polar map analysis). To facilitate standardized analyses, we intentionally did not change the technique in the course of time. New studies in our center being currently initiated refer to current standards such as early and late imaging and heart-to-mediastinum ratios.

The decision for implantation of an ICD, which was not part of the study, was based on guidelines existing at the time of diagnosis irrespective of the results of ^{123}I-MIBG SPECT and on the patient's choice. Genetic analysis focused on the presence or absence of *PKP-2* mutations, which underlie up to 43% of ARVC patients (5), and was complete in all patients. However, information on other known desmosomal gene mutations was incomplete.

The present study was not designed to confirm or refute a potential causal relation of sympathetic dysfunction and predominantly right ventricular tachyarrhythmias. Standard ^{123}I-MIBG SPECT is restricted to the left ventricle, and thus no direct information on the sympathetic innervation of the right ventricle can currently be provided by SPECT techniques. However, the high incidence of abnormal ^{123}I-MIBG SPECT not only in ARVC patients but also in patients with known nonstructural LV abnormalities such as RV outflow-tract tachycardias (8), or with the Brugada syndrome (7) or long-QT syndrome (13), may underscore the value of ^{123}I-MIBG SPECT.

In addition, this study cannot finally resolve the question of whether a reduced receptor density or a reduction of sympathetic capacity itself results in an innervation defect as made visible by ^{123}I-MIBG SPECT. To date, no technical means are available to answer this question.

Over recent years, B-type natriuretic peptides and other biomarkers have gained increasing widespread recognition in clinical medicine facilitated by tests then commercially available (14). However, analysis of cardiac biomarkers was not part of this study, which started as early as 1992.

CONCLUSION

Presynaptic adrenergic dysfunction assessed by the regional reduction of myocardial uptake is associated with a markedly higher risk of future recurrent life-threatening ventricular tachyarrhythmias in patients with ARVC. ^{123}I-MIBG imaging may therefore help to establish an individualized risk stratification to minimize the propensity for ventricular tachyarrhythmias and sudden death in patients with ARVC.

DISCLOSURE STATEMENT

The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

ACKNOWLEDGMENTS

REFERENCES

1. Jacobson AF, Senior R, Cerqueira MD, et al. ADMIRE-HF Investigators. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure: results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. *J Am Coll Cardiol.* 2010;55:2212–2221.

2. Wichter T, Hindricks G, Lerch H, et al. Regional myocardial sympathetic dysinnervation in arrhythmogenic right ventricular cardiomyopathy: an analysis using ^{123}I-meta-iodobenzylguanidine scintigraphy. *Circulation.* 1994;89:667–683.

3. Marcus FI, Fontaine GH, Guiraudon G, et al. Right ventricular dysplasia: a report of 24 cases. *Circulation.* 1982;65:384–398.

4. Gerull B, Heuser A, Wichter T, et al. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. *Nat Genet.* 2004;36:1162–1164.

5. Sen-Chowdhry S, Morgan RD, Chambers JC, McKenna WJ. Arrhythmogenic cardiomyopathy: etiology, diagnosis, and treatment. *Annu Rev Med.* 2010;61:233–253.

6. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. *Circulation.* 2010;121:1533–1541.

7. Wichter T, Matheja P, Eckardt L, et al. Cardiac autonomic dysfunction in Brugada syndrome. *Circulation.* 2002;105:702–706.

8. Schäfers M, Wichter T, Lerch H, et al. Cardiac ^{123}I-MIBG uptake in idiopathic ventricular tachycardia and fibrillation. *J Nucl Med.* 1999;40:1–5.

9. Wichter T, Schäfers M, Rhodes CG, et al. Abnormalities of cardiac sympathetic innervation in arrhythmogenic right ventricular cardiomyopathy. Quantitative assessment of presynaptic norepinephrine reuptake and postsynaptic β-adrenergic receptor density with positron emission tomography. *Circulation.* 2000;101:1552–1558.

10. Morozumi T, Kusuoka H, Fukuchi K, et al. Myocardial iodine-123-metaiodobenzylguanidine images and autonomic nerve activity in normal subjects. *J Nucl Med.* 1997;38:49–52.

11. Nagamatsu H, Momose M, Kobayashi H, Kusakabe K, Kasanuki H. Prognostic value of ^{123}I-metaiodobenzylguanidine in patients with various heart diseases. *Ann Nucl Med.* 2007;21:513–520.

12. Agostini D, Verberne HJ, Burchert W, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. *Eur J Nucl Med Mol Imaging.* 2008;35:535–546.

13. Göhl K, Feistel H, Weikl A, Bachmann K, Wolf F. Congenital myocardial sympathetic dysinnervation (CMSD)–a structural defect of idiopathic long QT syndrome. *Pacing Clin Electrophysiol.* 1991;14:1544–1553.

14. O'Donoghue M, Braunwald E. Natriuretic peptides in heart failure: should therapy be guided by BNP levels? *Nat Rev Cardiol.* 2010;7:13–20.

The Journal of NUCLEAR MEDICINE

Cardiac Sympathetic Dysfunction in Genotyped Patients with Arrhythmogenic Right Ventricular Cardiomyopathy and Risk of Recurrent Ventricular Tachyarrhythmias

Matthias Paul, Thomas Wichter, Peter Kies, Joachim Gerss, Christian Wollmann, Kambiz Rahbar, Lars Eckardt, Günter Breithardt, Otmar Schober, Eric Schulze-Bahr and Michael Schäfers

This article and updated information are available at:
http://jnm.snmjournals.org/content/52/10/1559

Information about reproducing figures, tables, or other portions of this article can be found online at:
http://jnm.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNM can be found at:
http://jnm.snmjournals.org/site/subscriptions/online.xhtml

SNMMI | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING